The significance of non-alcoholic fatty liver disease in atrial fibrillation development: view of cardiologist


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In recent years, a large amount of data proving the role of non-alcoholic fatty liver disease (NAFLD) in atrial fibrillation (AF) development has appeared. The key elements in the etiopathogenesis of AF in NAFLD are obesity, inflammation, carbohydrate and lipid metabolism disorders. The clinical course of AF in NAFLD is largely determined by the presence of additional risk factors for cardiovascular events, such as overweight, arterial hypertension, diabetes mellitus, and dyslipidemia. Patients with a high risk of cardiovascular complications are tending to have a fairly rapid progression of arrhythmias from paroxysmal to persistent or permanent form of AF. The tactics of NAFLD and AF patients' management includes anticoagulant therapy in case of an increased risk of thromboembolic complications, control of arrhythmia symptoms, treatment of comorbidities, and correction of risk factors. The most promising methods for the prevention of arrhythmia in patients with NAFLD include the use of ursodeoxycholic acid medications.

全文:

受限制的访问

作者简介

A. Tarzimanova

I.M. Sechenov First Moscow state medical university of the Ministry of Healthcare of Russia (Sechenov University)

Email: tarzimanova0mail.ru
119048, Moscow, 24 Efremova Str

参考

  1. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373-498. https://dx.doi.org/10.1093/eurheartj/ehaa612
  2. Haghbin H., Gangwani M.K., Ravi S.J.K. et al. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol. 2020; 33(6): 603-14. https://dx.doi.org/10.20524/aog.2020.0550.
  3. Sinner M.F., Wang N., Fox C.S. et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2013; 111(2): 219-24. https://dx.doi.org/10.1016/j.amjcard.2012.09.021.
  4. Karajamaki A.J., Patsi O.P., Savolainen M. et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One. 2015; 10(11): e0142937. https://dx.doi.org/10.1371/journal.pone.0142937.
  5. Маевская М.В., Котовская Ю.В., Ивашкин В.Т. с соавт. Национальный консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022; 2: 216253. @@Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T. et al. The national consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 2: 216-253 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2022.02.201363.
  6. Wong C.X., Sullivan T., Sun M.T. et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: A metaanalysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015; 1(3): 139-52. https://dx.doi.org/10.1016/j.jacep.2015.04.004.
  7. Goudis C.A., Korantzopoulos P., Ntalas I.V. et al. Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015; 66(5): 361-69. https://dx.doi.org/10.1016/j.jjcc.2015.04.002.
  8. Bell J.A., Kivimaki M., Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obesity reviews. 2014; 15(6): 504-15. https://dx.doi.org/10.1111/obr.12157.
  9. Mahajan R., Lau D.H., Brooks A.G. et al. Electrophysiological, electroanatomical and structural remodeling of the atria as a consequence of sustained obesity. J Am Coll Cardiol. 2015; 66(1): 1-11. https://dx.doi.org/10.1016/j.jacc.2015.04.058.
  10. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2019; 1: 5-66. @@Oganov R.G., Simanenkov V.I., Bakulin I.G. et al.Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019; 1: 5-66 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2019-1-5-66.
  11. Фомина И.Г, Тарзиманова А.И., Ветлужский А.В., Абрамова А.А. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» - открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005; 4: 65-69. @@Fomina I.G., Tarzimanova A.I., Vetluzhsky A.V., Abramova A.A. Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY - an open, multicenter, pilot study performed in the Russian Federation (part II). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2005; 4: 65-69 (In Russ.)].
  12. Chang S.H., Wu L.S., Chiou M.J. et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014; 13: 123. https://dx.doi.org/10.1186/s12933-014-0123-x.
  13. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю. с соавт. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014; 12: 48-52. @@Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu. et al. Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: the RACURS study. Terapevticheskiy arkhiv = Therapeutic Archive. 2014; 12: 48-52 (in Russ.)]. https://dx.doi.org/10.17116/terarkh2014861248-52.
  14. Nadinskaia M., Maevskaya M., Ivashkin V. et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021; 27(10): 959-75. https://dx.doi.org/10.3748/wjg.v27.i10.959.
  15. von Haehling S., Schefold J.C., Jankowska E.A. et al. Ursodeoxycholic acid in patients with chronic heart failure: A double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012; 59(6): 585-92. https://dx.doi.org/10.1016/j.jacc.2011.10.880.
  16. Rainer P.P., Primessnig U., Harenkamp S. et al. Bile acids induce arrhythmias in human atrial myocardium - implications for altered serum bile acid composition in patients with atrial fibrillation. Heart. 2013; 99(22): 1685-92. https://dx.doi.org/10.1136/heartjnl-2013-304163.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##